Adenosine Triphosphate (ATP) News and Research

RSS

Researchers uncover molecular and clinical role of irisin in humans

A research team led by Dr. Christos Mantzoros, MD, PhD, at Beth Israel Deaconess Medical Center, Harvard Medical School, has published new findings elucidating the molecular and clinical role of FNDC5/irisin in humans.

1 Oct 2012

New understanding about functionality of CFTR protein

CFTR is an important protein that, when mutated, causes the life-threatening genetic disease cystic fibrosis. A study in The Journal of General Physiology (JGP) details how an accidental discovery has provided new understanding about CFTR functionality.

27 Sep 2012

Hyperuricemia associated with more severe hepatic ATP depletion in response to fructose intake

Obese patients with type 2 diabetes who consume higher amounts of fructose display reduced levels of liver adenosine triphosphate (ATP)—a compound involved in the energy transfer between cells.

14 Sep 2012

New infrared spectroscopy technique to analyze pharmacological agent-protein interactions

RUB-Researchers from the Chair for Biophysics have developed a new method for the detailed study of the interaction between pharmaceuticals and their target proteins.

5 Sep 2012

Subthreshold metabolic syndrome common in drug-naïve schizophrenia patients

Around 1 in 10 antipsychotic-naïve Indian patients with schizophrenia meet full criteria for the metabolic syndrome, but a significantly larger proportion have subthreshold metabolic syndrome, researchers report.

4 Sep 2012

DEAD-box proteins function as recycling nanopistons when unwinding RNA

AUSTIN, Texas-Molecular biologists at The University of Texas at Austin have solved one of the mysteries of how double-stranded RNA is remodeled inside cells in both their normal and disease states. The discovery may have implications for treating cancer and viruses in humans.

3 Sep 2012

Janssen submits bedaquiline MAA with EMA for treatment of multi-drug resistant tuberculosis

Janssen-Cilag International NV (Janssen) today announced it has submitted a Marketing Authorisation Application to the European Medicines Agency (EMA) seeking conditional approval for the use of the investigational drug bedaquiline (TMC207) as an oral treatment, to be used as part of combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults.

31 Aug 2012

ABCD4 and CblF proteins responsible for hereditary vitamin B12 deficiency

Vitamin B12 is vital for cell division, the synthesis of red blood cells and the functioning of the nervous system. Unable to produce the vitamin itself, the human body has to obtain it via animal proteins. So far it has been known that on its way into the cell vitamin B12 is absorbed by little organelles, so-called lysosomes. From there, the vitamin enters the cell interior with the aid of the transport protein CblF, which was discovered by the same research team three years ago.

28 Aug 2012

MitoTarget Project and neurodegenerative diseases: an interview with Rebecca Pruss, Ph.D., CSO of Trophos

The MitoTarget Project was a project funded by the European Commission, under their FP7 programme. It was funding for a call published in 2007.

21 Aug 2012

UCP2 uncoupling protein occurs mainly in cells of the immune system

When uncoupling proteins are active, mitochondria produce heat instead of ATP. This may be useful under certain circumstances, such as when an animal is hibernating. But non-hibernating animals also have them. Particularly poorly understood is the uncoupling protein UCP2. Elena Pohl and colleagues at the University of Veterinary Medicine, Vienna, show that the protein occurs mainly in cells of the immune system.

18 Aug 2012

Creatine may fight major depression in women

Women battling stubborn major depression may have a surprising new ally in their fight—the muscle-building dietary supplement creatine.

7 Aug 2012

Biomimetic bioartificial livers and cell toxicity assays: an interview with Dr. Joris Braspenning, CEO Medicyte

Biomimetic bioartificial livers are liver organoids based on synthetic equivalents of the human extracellular matrix (ECM) which will be seeded with human cells.

1 Aug 2012

D-ribose effective in improving QOL in energy-depleted patients with FMS/CFS

A new multicenter study published in The Open Pain Journal showed that daily consumption of the pentose carbohydrate D-ribose resulted in an average energy boost of 61 percent among patients diagnosed with Chronic Fatigue Syndrome (CFS) and fibromyalgia (FMS).

17 Jul 2012

New strategy to reduce or eliminate scars on the skin

Whether from surgery or battle wounds, ugly scars can affect body and mind. Now a new research report appearing online in the FASEB Journal offers a new strategy to reduce or eliminate scars on the skin.

7 Jul 2012

Scientists discover constant cloud of potent inflammatory molecules surrounding the monocytes

Scientists at the University of East Anglia (UEA) have discovered a 'constant cloud' of potent inflammatory molecules surrounding the cells responsible for diseases such as thickening of the arteries and rheumatoid arthritis.

5 Jul 2012

Study links procedural pain and detectable oxidative stress in neonates

There was a time when a belief was widely held that premature neonates did not perceive pain. That, of course, has been refuted but measurements of neonate pain tend to rely on inexact measures, such as alertness and ability to react expressively to pain sensations. Researchers at Loma Linda University reported in The Journal of Pain that there is a significant relationship between procedural pain and detectable oxidative stress in neonates.

2 Jul 2012

Janssen seeks accelerated FDA approval for bedaquiline to treat MDR-TB

Janssen Research & Development, LLC today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the use of the investigational drug bedaquiline (TMC207) as an oral treatment, to be used as part of combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults.

2 Jul 2012

HemoGenix receives first Master File Number from FDA CBER for HALO-96 PQR

HemoGenix announced today that FDA CBER has given HemoGenix its first Master File Number for an in vitro blood stem cell potency, quality and release assay (HALO-96 PQR) for cellular therapy products used for stem cell transplantation purposes. HALO-96 PQR is the first commercially available stem cell potency assay for cellular therapy products.

27 Jun 2012

Chronic kidney disease is major risk factor for future coronary events

People with chronic kidney disease have a 10-year risk for myocardial infarction of around 12%, report researchers who found that this was higher than that for people with diabetes.

26 Jun 2012

Enrollment commences in Stealth Peptides' Bendavia Phase II clinical study for acute STEMI

Stealth Peptides Incorporated, a privately held biopharmaceutical company developing innovative therapies for cardiovascular disease and its complications, announced today that the first patient was enrolled in its multinational Phase II clinical study with Bendavia focused on ischemia reperfusion and microvascular injuries for patients experiencing acute ST-segment elevation myocardial infarction.

25 Jun 2012